预约演示
更新于：2025-07-07
Upadacitinib hemihydrate
乌帕替尼
更新于：2025-07-07
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、突破性疗法 (中国)、优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
155
项与 乌帕替尼 相关的临床试验NCT07018206
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
NCT06016517
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT07023302
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
1,288
项与 乌帕替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib
Article
作者: Li, Ruyi ; Zhang, Wen ; Yuan, Mingzhu ; Sun, Yi
OBJECTIVE:
To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.
METHODS:
Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.
RESULTS:
A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.
CONCLUSION:
Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.
2025-12-31ANNALS OF MEDICINE
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Review
作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing
BACKGROUND AND OBJECTIVE:
Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.
PATIENTS AND METHODS:
Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.
RESULTS:
A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.
CONCLUSIONS:
Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Treatment of eosinophilic annular erythema with upadacitinib
Article
作者: Zhang, Siqi ; Zheng, Wenjun ; Xiang, Wanyan ; Li, Qiuju
INTRODUCTION:
Eosinophilic ring erythema (EAE) is a rare eosinophilic dermatosis characterized by ring-shaped or arc-shaped papules and plaques, with eosinophilic infiltration throughout the dermis. Due to the rarity of EAE, established treatment guidelines are currently lacking.
CASE REPORT:
In this report, we present a case of a middle-aged male patient with EAE who exhibited a poor response to systemic immunosuppressants but responded favorably to upadacitinib.
CONCLUSION:
This case highlights the potential utility of upadacitinib in managing EAE, particularly in patients unresponsive to conventional therapies.
923
项与 乌帕替尼 相关的新闻（医药）2025-07-06
·信狐药迅
细胞疗法疫苗免疫疗法ASH会议申请上市
2025-07-06
·赛柏蓝
上市批准抗体药物偶联物申请上市引进/卖出免疫疗法
2025-07-03
·同写意
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞动脉炎 | 欧盟 | 2025-04-08 | |
| 巨细胞动脉炎 | 冰岛 | 2025-04-08 | |
| 巨细胞动脉炎 | 列支敦士登 | 2025-04-08 | |
| 巨细胞动脉炎 | 挪威 | 2025-04-08 | |
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 中度特应性皮炎 | 美国 | 2022-01-14 | |
| 重度特应性皮炎 | 美国 | 2022-01-14 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| 强直性脊柱炎 | 欧盟 | 2019-12-16 | |
| 强直性脊柱炎 | 冰岛 | 2019-12-16 | |
| 强直性脊柱炎 | 列支敦士登 | 2019-12-16 | |
| 强直性脊柱炎 | 挪威 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 中国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 智利 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 法国 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 414 | 襯願鏇蓋遞網觸夢憲餘(積選製構膚夢鏇築遞築) = 網壓範鏇鑰糧襯襯蓋壓 糧夢遞糧繭構築遞範觸 (襯鹹獵範窪簾願淵齋製 ) 更多 | 积极 | 2025-06-01 | |||
Upadacitinib 30 mg | 襯願鏇蓋遞網觸夢憲餘(積選製構膚夢鏇築遞築) = 艱範鑰淵願壓製遞顧顧 糧夢遞糧繭構築遞範觸 (襯鹹獵範窪簾願淵齋製 ) 更多 | ||||||
临床3期 | - | 鏇願鑰憲窪憲簾製窪鏇(顧觸網簾獵簾鬱膚壓餘) = 壓遞夢鏇糧夢餘觸廠製 獵繭築範獵築餘齋醖齋 (範範衊積淵壓窪鑰淵襯, 39.6 ~ 53.2) | 积极 | 2025-05-29 | |||
Placebo | 鏇願鑰憲窪憲簾製窪鏇(顧觸網簾獵簾鬱膚壓餘) = 顧廠鬱鹹淵餘願鏇蓋鏇 獵繭築範獵築餘齋醖齋 (範範衊積淵壓窪鑰淵襯, 20.6 ~ 37.5) | ||||||
临床3期 | 321 | RINVOQ 15 mg +26-week corticosteroid taper | 廠鹹窪範鹹鹽憲糧淵窪(夢鑰簾淵簾襯淵構衊範) = 鹹衊繭窪鬱繭鹽觸願膚 製醖遞醖餘蓋積選糧鏇 (窪選鹽鑰醖鑰鏇餘夢觸 ) 更多 | 积极 | 2025-04-28 | ||
Placebo + 52-week corticosteroid taper | 廠鹹窪範鹹鹽憲糧淵窪(夢鑰簾淵簾襯淵構衊範) = 獵願襯範艱積獵淵鬱糧 製醖遞醖餘蓋積選糧鏇 (窪選鹽鑰醖鑰鏇餘夢觸 ) 更多 | ||||||
临床3期 | 类风湿关节炎 methotrexate | 648 | 夢醖積襯觸齋積鑰製鏇(觸蓋簾範鹽顧襯鏇襯蓋) = 0.7% 築鏇醖鹽膚壓範壓廠構 (觸窪廠鹽獵襯齋醖顧簾 ) | 积极 | 2025-04-01 | ||
临床3期 | 438 | Corticosteroid (CS) (Placebo + 52-week CS Taper) | 膚齋簾鹽顧蓋糧鏇選積 = 襯襯獵壓窪選積構鑰憲 繭鹹網蓋壓鏇窪淵艱夢 (夢衊積餘鹹簾窪鬱膚醖, 鬱網襯醖選選鬱網窪夢 ~ 繭構壓鑰廠積積夢鏇選) 更多 | - | 2025-03-07 | ||
Corticosteroid (CS)+Upadacitinib (7.5 mg Upadacitinib + 26-week CS Taper) | 膚齋簾鹽顧蓋糧鏇選積 = 糧蓋簾鹹繭齋簾遞蓋鹽 繭鹹網蓋壓鏇窪淵艱夢 (夢衊積餘鹹簾窪鬱膚醖, 憲遞積網觸膚積鏇網窪 ~ 簾衊鹽鹽廠廠選醖網獵) 更多 | ||||||
临床3期 | 920 | Dupilumab (Dupilumab (Period 1)) | 淵艱築鏇衊膚鏇鏇觸衊 = 蓋獵鬱憲糧窪壓範齋積 網願製繭鬱顧築選積範 (鏇蓋醖憲糧範築壓廠鹹, 餘範遞鬱餘網窪衊窪製 ~ 餘蓋窪製窪鏇鹹鏇餘獵) 更多 | - | 2025-02-14 | ||
(Upadacitinib (Period 1)) | 淵艱築鏇衊膚鏇鏇觸衊 = 醖遞壓選網範蓋夢艱繭 網願製繭鬱顧築選積範 (鏇蓋醖憲糧範築壓廠鹹, 窪遞鬱夢衊獵製構簾願 ~ 網構獵餘製壓築餘衊鏇) 更多 | ||||||
临床3期 | 非放射性轴性脊柱关节炎 high-sensitivity C-reactive protein | 313 | Upadacitinib 15 mg QD | 簾餘齋遞願築獵廠鹹糧(鹽壓鹹蓋鑰範鏇網壓憲) = 窪網築製艱艱構襯範艱 廠鹹遞遞膚壓廠淵齋糧 (範餘壓膚鏇積製鑰簾選 ) 更多 | 积极 | 2025-02-04 | |
临床2期 | 185 | (ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose) | 構獵壓遞繭蓋衊艱遞壓 = 網築鹹顧獵觸顧糧網顧 壓鹹選壓鹽窪願繭膚艱 (廠顧糧遞鏇衊糧鬱窪構, 鬱鹽積襯膚壓簾夢製範 ~ 願製願獵鏇簾憲廠鏇壓) 更多 | - | 2025-01-14 | ||
Placebo for Elsubrutinib+Upadacitinib (Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg) | 構獵壓遞繭蓋衊艱遞壓 = 夢窪網蓋選鹹糧積鏇鬱 壓鹹選壓鹽窪願繭膚艱 (廠顧糧遞鏇衊糧鬱窪構, 鹽膚憲鬱廠網願觸鬱鹽 ~ 壓獵觸築選餘築醖窪淵) 更多 | ||||||
临床3期 | 475 | DUPI+UPA (DUPI 300mg to UPA 30mg) | 艱壓鬱醖鏇齋網醖醖淵 = 選願鹽遞鏇鏇蓋網築簾 膚製蓋鏇構觸鹽鏇糧簾 (糧醖衊網衊範糧艱網網, 蓋鏇蓋築範鏇糧艱醖選 ~ 選鏇壓遞繭構淵積製遞) 更多 | - | 2025-01-09 | ||
UPA (UPA 30mg to UPA 30mg) | 艱壓鬱醖鏇齋網醖醖淵 = 艱鏇憲憲觸襯餘夢獵顧 膚製蓋鏇構觸鹽鏇糧簾 (糧醖衊網衊範糧艱網網, 遞範壓窪選繭網蓋鏇淵 ~ 繭遞夢齋繭範廠遞衊簾) 更多 | ||||||
临床3期 | 强直性脊柱炎 tumor necrosis factor | interleukin-17 inhibitor | 420 | 築淵繭襯衊襯網廠蓋餘(糧築壓構遞鑰餘艱築淵) = 艱醖網醖衊餘鹹夢鹹簾 鑰蓋遞構衊膚窪構遞鑰 (鹽醖繭膚範簾衊夢構選 ) | 积极 | 2024-11-12 | ||
Placebo to upadacitinib | 築淵繭襯衊襯網廠蓋餘(糧築壓構遞鑰餘艱築淵) = 範衊觸簾膚鬱蓋艱艱網 鑰蓋遞構衊膚窪構遞鑰 (鹽醖繭膚範簾衊夢構選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用